Abstract
Antibody drug conjugates intends to pursue the monoclonal antibodies (mAbs) as the potent source of delivering cytotoxic drugs to more specific site which binds selectively to the antigen expressing tumor cells. Inspite of the facts, various other safety profile must be considered while designing and optimizing ADC such as selecting congruous target antigen and method of conjugation. Each and every component of the ADC i.e antibody, linker and the drug should be optimized to the extent of desirable targeted therapy which will ameliorate as well as enhance tolerability. The past decade had witnessed advances in newer cancer treatments with extremely selective small molecules targeting the specific genetic abnormality causing the disease. The approach of traditional cytotoxic agents in the treatment of cancer, unlike the target specificity, they affect both healthy as well as cancer cells. In order to build a powerful and more specific cytotoxic agent with target oriented mAb’s designing attributes would lead to pertinent and potential breakthrough in cancer treatments. Therefore ADC’s were developed with the intention that antibody would target the specific antigen of the tumor wherein the drug attached to it would induce its cytotoxicity. Developement of new techniques and methods in implementing new generation ADC’s in the past decades incorporated non-immunogenic monoclonal antibodies comprising linkers having equitable stability and distinctly potent cytotoxic agents. Newer challenges although remain but comprehensive clinical accomplishment is generating increased interest in this therapeutic class of drugs.
Highlights
Bioconjugation strategies offer promising therapeutic benefits by synergy of those of the individual components [1,2]
This review article intends to exemplify the proposed challenges, mechanism of action, therapeutic efficacy and safety level parameters which are in association with the judicious use of Antibody Drug Conjugates (ADCs)’s thereby enhancing the improvement in the upcoming treatment methods in medical science
Study Methodology More than 50 relevant articles from indexed journals were extensively reviewed based on the keywords- Bioconjugation, Antibody Drug Conjugation, site-specific conjugation, ADCs cytotoxic payload, etc. from PubMed central and Google Scholar with special emphasis on articles published after 2014
Summary
Bioconjugation strategies offer promising therapeutic benefits by synergy of those of the individual components [1,2]. Bioconjugates like Antibody Drug Conjugates (ADCs) in targeted oncology research is found to improve the durability of anti-tumor responses in cancer patients [4,5,6,7,8,9,10,11,12,13]. This review article intends to exemplify the proposed challenges, mechanism of action, therapeutic efficacy and safety level parameters which are in association with the judicious use of ADC’s thereby enhancing the improvement in the upcoming treatment methods in medical science. This developmental process which targets the payloads would be prospective enough to bridge the gap in future findings
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Clinical and Biomedical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.